We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Journal of Comparative Effectiveness Research
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine

The patient’s perspective of gout

    Romy Aranguiz

    Romy Aranguiz is a second-year adult rheumatology fellow at the University of Massachusetts Medical School (USA). She finished her internal medicine residency at the New Jersey Medical School (USA) and attended medical school at Belize Medical College (Belize).

    Search for more papers by this author

    &
    Leslie R Harrold

    Leslie R Harrold is a rheumatologist and Associate Professor at the University of Massachusetts Medical School. She has received federal and foundation funding to study the management of patients with chronic musculoskeletal conditions, examine ways to improve medication adherence with arthritis therapies and evaluate barriers to receipt of optimal care. Her work on gout has included an examination of gender-related differences in the epidemiology and treatment of patients with gout, as well as an assessment of gout knowledge and beliefs through use of questionnaires to both patient and providers.

    Search for more papers by this author

    Published Online:18 Jul 2013https://doi.org/10.2217/ebo.12.445
    Abstract:

    This chapter reviews the current literature on patient’s perceptions in reference to gout etiology and management. Lack of knowledge about disease stages, related comorbidities, specific treatment for each state of gout, common side effects of medications and long-term consequences of inadequate care has been demonstrated among patients with gout. These knowledge deficits and the lack of patient self-management training have been associated with poor adherence to recommended therapies, thus leading to recurrent suboptimal care of gout; the most common inflammatory joint disease and the only one for which there is potentially curative therapy. This chapter examines the importance of the patient’s knowledge, cultural beliefs and management preferences of the disease in general, as well as for each specific stage. Recommendations have also been provided to physicians in order to identify concrete ways to improve patient care in terms of patient education and self-management training in an effort to reinforce successful strategies and behaviors towards controlling the condition.

    References

    • 1  Neogi T . Gout . N. Engl. J. Med. 364 , 443 – 452 (2011) . Crossref, Medline, CAS, Google Scholar
    • 2  Becker MA , Schumacher HR , Benjamin KL et al. Quality of life and disability in patients with treatment-failure gout . J. Rheumatol. 36 , 1041 – 1048 (2009) . Crossref, Medline, Google Scholar
    • 3  Lee SJ , Hirsch JD , Terkeltaub R et al. Perceptions of disease and health-related quality of life among patients with gout . Rheumatology 48 , 582 – 586 (2009) . Crossref, Medline, Google Scholar
    • 4  Spencer K , Carr A , Doherty M . Patient and providers barriers to effective management of gout in general practice: a qualitative study . Ann. Rheum. 71 , 1490 – 1495 (2012) . Crossref, Medline, Google Scholar
    • 5  Harrold LR , Mazor KM , Peterson D , Naz N , Firneno C , Yood R . Patients knowledge and beliefs concerning gout and its treatment . BMC Musculoskelet. Disord. 13 , 180 (2012) . Crossref, Medline, Google Scholar
    • 6  Singh JA , Strand V . Quality of life and quality of care for patients with gout . Curr. Rheumatol. Rep. 11 , 154 – 160 (2009) . Crossref, Medline, Google Scholar
    • 7  Harrold LR , Andrade SE , Briesacher BA et al. Adherence with urate-lowering therapies for the treatment of gout . Arthritis Res. Ther. 1 , R46 (2009) . Crossref, Google Scholar
    • 8  Schlesinger N . Management of acute and chronic gouty arthritis: present state-of-the-art . Drugs 64 (21) , 2399 – 2416 (2004) . Crossref, Medline, CAS, Google Scholar
    • 9  Richette P , Ottaviani S , Bardin T et al. [New therapeutic options for gout] . Presse Med. 40 (9 Pt 1) , 844 – 849 (2011) . Crossref, Medline, Google Scholar
    • 10  Schumacher HR Jr , Sundy JS , Terkeltaub R et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a Phase II randomized, double-blind, placebo-controlled trial . Arthritis Rheum. 64 (3) , 876 – 884 (2012) . Crossref, Medline, CAS, Google Scholar
    • 11  Dalbeth N , Petrie KJ , House M et al. Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability . Arthritis Care Res. (Hoboken) 63 , 1605 – 1612 (2011) . Crossref, Medline, Google Scholar
    • 12  Zhang Y , Chen C , Choi H et al. Purine-rich foods intake and recurrent gout attacks . Ann. Rheum. Dis. 71 (9) , 1448 – 1453 (2012) . Crossref, Medline, CAS, Google Scholar
    • 13  Brixner DI , Ho MJ . Clinical humanistic and economic outcomes of gout . Am. J. Manag. Care 11 , S459 – S464 (2005) . Medline, Google Scholar
    • 14  Kesselheim AS , Solomon DH . Incentives for drug development – the curious case of colchicines . N. Engl. J. Med. 362 , 2045 – 2047 (2010) . Crossref, Medline, CAS, Google Scholar
    • 15  Sarawate CA , Breer KK . Gout medication treatment patterns and adherence to standards of care from a manage care patients perspective . Mayo Clin. Proc. 81 (7) , 925 – 934 (2006) . Crossref, Medline, Google Scholar